Drug Discovery World
DECEMBER 14, 2023
Early operations focused on the discovery of green fluorescent protein (GFP), which played a very big role in early drug discovery research operations using cellular assays. But it comes with surface charge that will absorb proteins, DNA, and other things, unless you do something to treat that surface.
Drug Discovery World
MARCH 2, 2023
AVA6000 is a pre|CISION tumour-targeted form of the established chemotherapy doxorubicin; designed to limit cell penetration of the drug — and therefore its cell killing effect — until it is specifically activated by fibroblast activation protein α (FAP), which is in high concentration in many solid tumours compared with healthy tissues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 28, 2023
mRNA enables the delivery of a transiently expressed genetic molecule that is translated into a target protein using the machinery of the host cell. Therefore, the risk for off-target insertional mutagenesis is greatly reduced. In addition, it may be easier to target the therapeutic molecule to the correct cell or tissue.
pharmaphorum
APRIL 5, 2022
The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs. The post AI test could predict best cancer therapies for patients appeared first on.
XTalks
DECEMBER 15, 2020
Plant proteins , milk alternatives , meat alternatives , bee-less honey , lab-grown meat and more are all kinds of innovations we have seen in 2020, but studies show that plant-based trends are still on the rise as new technologies are developed to cater to this market.
XTalks
DECEMBER 15, 2020
Plant proteins , milk alternatives , meat alternatives , bee-less honey , lab-grown meat and more are all kinds of innovations we have seen in 2020, but studies show that plant-based trends are still on the rise as new technologies are developed to cater to this market.
XTalks
MARCH 7, 2024
The company’s ResolveOME multiomic workflow provides a comprehensive multiomic analysis of breast cancer through the use of exome hybrid capture alongside a single-cell workflow for single-cell resolution of single nucleotide variants (SNVs), copy number alterations and gene expression signatures, coupled with a targeted protein panel.
Expert insights. Personalized for you.
52 
Let's personalize your content